Alan Barge

Alan Barge is the Co-Founder, Director, and CEO of Tilikum Therapeutics, a biotechnology company developing a new class of small-molecule cancer therapies.1 He brings extensive experience in oncology drug development to his role at Tilikum.

Professional Background

Dr. Barge has over 25 years of experience in cancer drug development.5 Prior to co-founding Tilikum Therapeutics, he held significant positions in the pharmaceutical industry:

• Vice President of Oncology at AstraZeneca, where he played a key role in developing important cancer drugs like Iressa and Lynparza.1
• Venture Partner at Delin Ventures Ltd.4
• Senior Independent Non-executive Director at TheraCryf Plc.4

Expertise and Reputation

Alan Barge is known for his:

• Legendary drug development skills: He is highly regarded in the industry for his expertise in this area.2
• Leadership abilities: He excels in leadership roles and is considered an excellent communicator and presenter.2
• Medical background: Dr. Barge is a board-certified oncologist and hematologist.5

Current Role at Tilikum Therapeutics

At Tilikum, Dr. Barge is leading the development of next-generation PARP inhibitors.3 The company's focus is on creating novel cancer therapies that can overcome resistance mechanisms and treat solid tumors that don't respond to currently approved drugs.1

Alan Barge's extensive experience in oncology and drug development, combined with his leadership skills, positions him well to guide Tilikum Therapeutics in its mission to advance cancer treatment options.